Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance

Bahr, Matthias J.; Ockenga, Johann; Böker, K. H. W.; Manns, Michael P.; Tietge, Uwe J. F.

doi:10.1152/ajpendo.00291.2005

Cited by 38 publications

(33 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results have evidenced that high circulating levels of these molecules are correlated to the presence of fasting glucose in cirrhotic patients due to reduced liver function and altered hepatic glucose metabolism in agreement to previous papers [33]–[39]. However, it is important to underline that the same molecules increased in CHC and LC patients with the sole exception of HGF that can be used for predicting the progression to HCC in patients with CHC-related liver disease and low albumin.…”

Section: Resultssupporting

confidence: 90%

Cytokinome Profile of Patients with Type 2 Diabetes and/or Chronic Hepatitis C Infection

Costantini¹,

Capone²,

Guerriero³

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

Both type 2 diabetes (T2D) and chronic hepatitis C (CHC) infection are associated with increased risk of developing hepatocellular carcinoma (HCC). Cytokines are known to play an important role not only in the mechanisms of insulin resistance and glucose disposal defects but also in the pathological processes occurring in the liver during viral infection. We evaluated the serum levels of many cytokines, chemokines, adipokines and growth factors in patients with type 2 diabetes, CHC, CHC-related cirrhosis, CHC and type 2 diabetes and CHC-related cirrhosis and type 2 diabetes by BioPlex assay. The obtained data evidenced that the serum levels of some proteins are significantly up-regulated in all the patients or in those with only one disease and are often higher, even if in different amounts, when both diseases are associated. In particular, our results can be useful for the clinical monitoring of patients because they give specific information in regard to the progression from CHC to LC and CHD to LCD. Moreover, some molecules have shown significant correlations with clinical/biochemical data, suggesting the possibility to define mini-panels that can be used as specific markers for the different disease staging. However, our observations demonstrate that an integrated approach is much more powerful than isolated measurements to evaluate specific stages of these two complex pathologies (type 2 diabetes and chronic CHC hepatitis) alone or when they are concomitant in a patient. In fact it has emerged as an accurate, simple, specific, noninvasive, reproducible and less expensive method that, in future, could be included in routine clinical practice to monitor the association of type 2 diabetes and/or CHC to liver cirrhosis and, possibly, to cancer, and to improve the prognosis of these diseases.

show abstract

Section: Resultssupporting

confidence: 90%

Cytokinome Profile of Patients with Type 2 Diabetes and/or Chronic Hepatitis C Infection

Costantini¹,

Capone²,

Guerriero³

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…The liver is a central organ in gluconeogenesis metabolism (Bechmann et al, 2012). Usually after liver injury, there would be glucose metabolic disorder (Bahr et al, 2006) and abnormal liver development (Yin et al, 2013). According to our discussion above, we figured out that the toxicity of CCl 4 may be associated with many biological processes.…”

Section: Discussionmentioning

confidence: 86%

Mechanisms of CCl<sub>4</sub>-induced liver fibrosis with combined transcriptomic and proteomic analysis

et al. 2016

View full text Add to dashboard Cite

-The classic toxicity of carbon tetrachloride (CCl 4 ) is to induce liver lesion and liver fibrosis. Liver fibrosis is a consequence of chronic liver lesion, which can progress into liver cirrhosis even hepatocarcinoma. However, the toxicological mechanisms of CCl 4 -induced liver fibrosis remain not fully understood. We combined transcriptomic and proteomic analysis and biological network technology, predicted toxicological targets and regulatory networks of CCl 4 in liver fibrosis. Wistar rats were treated with CCl 4 for 9 weeks. Histopathological changes, hydroxyproline (Hyp) contents, serum ALT and AST in the CCl 4 -treated group were significantly higher than that of CCl 4 -untreated group. CCl 4 -treated and -untreated liver tissues were examined by microarray and iTRAQ. The results showed that 3535 genes (fold change ≥ 1.5, P < 0.05) and 1412 proteins (fold change ≥ 1.2, P < 0.05) were differentially expressed. Moreover, the integrative analysis of transcriptomics and proteomics data showed 523 overlapped proteins, enriched in 182 GO terms including oxidation reduction, response to oxidative stress, inflammatory response, extracellular matrix organization, etc. Furthermore, KEGG pathway analysis showed that 36 pathways including retinol metabolism, PPAR signaling pathway, glycolysis/gluconeogenesis, arachidonic acid metabolism, metabolism of xenobiotics by cytochrome P450 and drug metabolism. Network of protein-protein interaction (PPI) and key function with their related targets were performed and the degree of network was calculated with Cytoscape. The expression of key targets such as CYP4A3, ALDH2 and ALDH7A1 decreased after CCl 4 treatment. Therefore, the toxicological mechanisms of CCl 4 -induced liver fibrosis may be related with multi biological process, pathway and targets which may provide potential protection reaction mechanism for CCl 4 detoxication in the liver.

show abstract

“…Resting energy expenditure (REE) was measured using indirect calorimetry as described (colesevalam-HCl study: Sensormedics, Yorba Linda, CA; cirrhosis study: Deltatrac metabolic monitor; Datex Instruments, Helsinki, Finland) [4]. Measured REE values were related to REE values predicted for healthy subjects using the Harris-Benedict formula [5].…”

Section: Methodsmentioning

confidence: 99%

Plasma bile acids are not associated with energy metabolism in humans

et al. 2010

Self Cite

View full text Add to dashboard Cite

Bile acids (BA) have recently been shown to increase energy expenditure in mice, but this concept has not been tested in humans. Therefore, we investigated the relationship between plasma BA levels and energy expenditure in humans. Type 2 diabetic (T2DM) patients (n = 12) and gender, age and BMI-matched healthy controls (n = 12) were studied before and after 8 weeks of treatment with a BA sequestrant. In addition, patients with liver cirrhosis (n = 46) were investigated, since these display elevated plasma BA together with increased energy expenditure. This group was compared to gender-, age- and BMI-matched healthy controls (n = 20). Fasting plasma levels of total BA and individual BA species as well as resting energy expenditure were determined. In response to treatment with the BA sequestrant, plasma deoxycholic acid (DCA) levels decreased in controls (-60%, p < 0.05) and T2DM (-32%, p < 0.05), while chenodeoxycholic acid (CDCA) decreased in controls only (-33%, p < 0.05). Energy expenditure did not differ between T2DM and controls at baseline and, in contrast to plasma BA levels, was unaffected by treatment with the BA sequestrant. Total BA as well as individual BA species did not correlate with energy expenditure at any time throughout the study. Patients with cirrhosis displayed on average an increase in energy expenditure of 18% compared to values predicted by the Harris-Benedict equation, and plasma levels of total BA (up to 12-fold) and individual BA (up to 20-fold) were increased over a wide range. However, neither total nor individual plasma BA levels correlated with energy expenditure. In addition, energy expenditure was identical in patients with a cholestatic versus a non-cholestatic origin of liver disease while plasma total BA levels differed four-fold between the groups. In conclusion, in the various (patho)physiological conditions studied, plasma BA levels were not associated with changes in energy expenditure. Therefore, our data do not support an important role of circulating BA in the control of human energy metabolism.

show abstract

Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance

Cited by 38 publications

References 52 publications

Cytokinome Profile of Patients with Type 2 Diabetes and/or Chronic Hepatitis C Infection

Cytokinome Profile of Patients with Type 2 Diabetes and/or Chronic Hepatitis C Infection

Mechanisms of CCl<sub>4</sub>-induced liver fibrosis with combined transcriptomic and proteomic analysis

Plasma bile acids are not associated with energy metabolism in humans

Contact Info

Product

Resources

About